Clinical evaluation of psychotropic drugs for psychiatric disorders: principles and proposed guidelines
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Seattle [u.a.]
Hogrefe & Huber
1993
|
| Schriftenreihe: | World Health Organization: WHO expert series on biological psychiatry
2 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | VII, 202 S. graph. Darst. |
| ISBN: | 3456820275 088937063X |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV007663775 | ||
| 003 | DE-604 | ||
| 005 | 19970117 | ||
| 007 | t | ||
| 008 | 930524s1993 d||| |||| 00||| eng d | ||
| 020 | |a 3456820275 |9 3-456-82027-5 | ||
| 020 | |a 088937063X |9 0-88937-063-X | ||
| 035 | |a (OCoLC)23355231 | ||
| 035 | |a (DE-599)BVBBV007663775 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-20 |a DE-578 | ||
| 050 | 0 | |a RC483 | |
| 082 | 0 | |a 616.89/061 |2 20 | |
| 245 | 1 | 0 | |a Clinical evaluation of psychotropic drugs for psychiatric disorders |b principles and proposed guidelines |c Paul Grof ... |
| 264 | 1 | |a Seattle [u.a.] |b Hogrefe & Huber |c 1993 | |
| 300 | |a VII, 202 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a World Health Organization: WHO expert series on biological psychiatry |v 2 | |
| 650 | 4 | |a Maladies mentales - Chimiothérapie | |
| 650 | 4 | |a Psychotropes | |
| 650 | 4 | |a Drug Evaluation |x standards | |
| 650 | 4 | |a Drug Utilization | |
| 650 | 4 | |a Mental Disorders |x drug therapy | |
| 650 | 4 | |a Mental illness |x Chemotherapy | |
| 650 | 4 | |a Psychotropic Drugs | |
| 650 | 4 | |a Psychotropic Drugs |x adverse effects | |
| 650 | 4 | |a Psychotropic drugs | |
| 650 | 4 | |a Substance-Related Disorders | |
| 650 | 0 | 7 | |a Evaluation |0 (DE-588)4071034-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Klinische Prüfung |0 (DE-588)4031192-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Psychopharmakon |0 (DE-588)4047729-0 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Psychopharmakon |0 (DE-588)4047729-0 |D s |
| 689 | 0 | 1 | |a Klinische Prüfung |0 (DE-588)4031192-2 |D s |
| 689 | 0 | 2 | |a Evaluation |0 (DE-588)4071034-8 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Grof, Paul |e Sonstige |4 oth | |
| 830 | 0 | |a World Health Organization: WHO expert series on biological psychiatry |v 2 |w (DE-604)BV005800405 |9 2 | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=005025244&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-005025244 | ||
Datensatz im Suchindex
| _version_ | 1804122017728823296 |
|---|---|
| adam_text | - 960 7 PAUL GROF, M. IFTIKHAR AKHTER, MAGDA CAMPBELL, CARL G.
GOTTFRIES, INAYAT KHAN, YVON D. LAPIERRE, LOUIS LEMBERGER, BRUNO
MIILLER-OERLINGHAUSEN, BRIGITTE WOGGON CLINICAL EVALUATION OF
PSYCHOTROPIC DRUGS FOR PSYCHIATRIC DISORDERS PRINCIPLES AND PROPOSED
GUIDELINES PUBLISHED ON BEHALF OF THE WORLD HEALTH ORGANIZATION BY
HOGREFE & HUBER PUBLISHERS SEATTLE * TORONTO * BERN * GOTTINGEN LIST OF
CONTENTS PREFACE 1 INTRODUCTION: 3 1. PURPOSE OF THE DOCUMENT 3 2. WHO
FRAMEWORK FOR THE DOCUMENT 4 3. DEVELOPMENT OF THE DOCUMENT 5 4. FORMAT
OF THE DOCUMENT 6 5. APPLICATION OF THE DOCUMENT 7 AN OVERVIEW OF DRUG
EVALUATION: 11 1. PHASES OF DRUG EVALUATION 11 2. PRECLINICAL
CONSIDERATIONS 12 3. CLINICAL STUDIES 16 4. GENERAL METHODOLOGICAL
ISSUES 18 5. ETHICAL CONSIDERATIONS 25 CHAPTER ONE: CLINICAL
PHARMACOLOGIC STUDIES 31 CHAPTER TWO: EARLY THERAPEUTIC STUDIES 59
CHAPTER THREE: MAIN THERAPEUTIC STUDIES 81 CHAPTER FOUR: EXPANDED
THERAPEUTIC STUDIES AND DRUG SURVEILLANCE 103 CHAPTER FIVE: STUDIES IN
CHILDREN 121 CHAPTER SIX: STUDIES IN THE ELDERLY 145 CHAPTER SEVEN:
TRANSCULTURAL ISSUES AFFECTING PSYCHO- TROPIC DRUG EVALUATION 167
GLOSSARY 181 ACKNOWLEDGEMENTS 184 SELECTED WHO PUBLICATIONS RELATED TO
PSYCHOPHARMACOLOGY ... 186 REFERENCES RECOMMENDED FOR FURTHER READING
188 REFERENCES TO THE CITED INSTRUMENTS AND STUDIES 191 VI LIST OF
TABLES 197 LIST OF FIGURES 197 LIST OF DIAGRAMS 198 APPENDIX:
DECLARATION OF HELSINKI 199 VII
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV007663775 |
| callnumber-first | R - Medicine |
| callnumber-label | RC483 |
| callnumber-raw | RC483 |
| callnumber-search | RC483 |
| callnumber-sort | RC 3483 |
| callnumber-subject | RC - Internal Medicine |
| ctrlnum | (OCoLC)23355231 (DE-599)BVBBV007663775 |
| dewey-full | 616.89/061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.89/061 |
| dewey-search | 616.89/061 |
| dewey-sort | 3616.89 261 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02118nam a2200529 cb4500</leader><controlfield tag="001">BV007663775</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">19970117 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">930524s1993 d||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3456820275</subfield><subfield code="9">3-456-82027-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">088937063X</subfield><subfield code="9">0-88937-063-X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)23355231</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV007663775</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-20</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC483</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.89/061</subfield><subfield code="2">20</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical evaluation of psychotropic drugs for psychiatric disorders</subfield><subfield code="b">principles and proposed guidelines</subfield><subfield code="c">Paul Grof ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Seattle [u.a.]</subfield><subfield code="b">Hogrefe & Huber</subfield><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">VII, 202 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">World Health Organization: WHO expert series on biological psychiatry</subfield><subfield code="v">2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Maladies mentales - Chimiothérapie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychotropes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Evaluation</subfield><subfield code="x">standards</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Utilization</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mental Disorders</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mental illness</subfield><subfield code="x">Chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychotropic Drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychotropic Drugs</subfield><subfield code="x">adverse effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychotropic drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Substance-Related Disorders</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Evaluation</subfield><subfield code="0">(DE-588)4071034-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Klinische Prüfung</subfield><subfield code="0">(DE-588)4031192-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Psychopharmakon</subfield><subfield code="0">(DE-588)4047729-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Psychopharmakon</subfield><subfield code="0">(DE-588)4047729-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Klinische Prüfung</subfield><subfield code="0">(DE-588)4031192-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Evaluation</subfield><subfield code="0">(DE-588)4071034-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grof, Paul</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">World Health Organization: WHO expert series on biological psychiatry</subfield><subfield code="v">2</subfield><subfield code="w">(DE-604)BV005800405</subfield><subfield code="9">2</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=005025244&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-005025244</subfield></datafield></record></collection> |
| id | DE-604.BV007663775 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T17:07:11Z |
| institution | BVB |
| isbn | 3456820275 088937063X |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-005025244 |
| oclc_num | 23355231 |
| open_access_boolean | |
| owner | DE-20 DE-578 |
| owner_facet | DE-20 DE-578 |
| physical | VII, 202 S. graph. Darst. |
| publishDate | 1993 |
| publishDateSearch | 1993 |
| publishDateSort | 1993 |
| publisher | Hogrefe & Huber |
| record_format | marc |
| series | World Health Organization: WHO expert series on biological psychiatry |
| series2 | World Health Organization: WHO expert series on biological psychiatry |
| spelling | Clinical evaluation of psychotropic drugs for psychiatric disorders principles and proposed guidelines Paul Grof ... Seattle [u.a.] Hogrefe & Huber 1993 VII, 202 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier World Health Organization: WHO expert series on biological psychiatry 2 Maladies mentales - Chimiothérapie Psychotropes Drug Evaluation standards Drug Utilization Mental Disorders drug therapy Mental illness Chemotherapy Psychotropic Drugs Psychotropic Drugs adverse effects Psychotropic drugs Substance-Related Disorders Evaluation (DE-588)4071034-8 gnd rswk-swf Klinische Prüfung (DE-588)4031192-2 gnd rswk-swf Psychopharmakon (DE-588)4047729-0 gnd rswk-swf Psychopharmakon (DE-588)4047729-0 s Klinische Prüfung (DE-588)4031192-2 s Evaluation (DE-588)4071034-8 s DE-604 Grof, Paul Sonstige oth World Health Organization: WHO expert series on biological psychiatry 2 (DE-604)BV005800405 2 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=005025244&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Clinical evaluation of psychotropic drugs for psychiatric disorders principles and proposed guidelines World Health Organization: WHO expert series on biological psychiatry Maladies mentales - Chimiothérapie Psychotropes Drug Evaluation standards Drug Utilization Mental Disorders drug therapy Mental illness Chemotherapy Psychotropic Drugs Psychotropic Drugs adverse effects Psychotropic drugs Substance-Related Disorders Evaluation (DE-588)4071034-8 gnd Klinische Prüfung (DE-588)4031192-2 gnd Psychopharmakon (DE-588)4047729-0 gnd |
| subject_GND | (DE-588)4071034-8 (DE-588)4031192-2 (DE-588)4047729-0 |
| title | Clinical evaluation of psychotropic drugs for psychiatric disorders principles and proposed guidelines |
| title_auth | Clinical evaluation of psychotropic drugs for psychiatric disorders principles and proposed guidelines |
| title_exact_search | Clinical evaluation of psychotropic drugs for psychiatric disorders principles and proposed guidelines |
| title_full | Clinical evaluation of psychotropic drugs for psychiatric disorders principles and proposed guidelines Paul Grof ... |
| title_fullStr | Clinical evaluation of psychotropic drugs for psychiatric disorders principles and proposed guidelines Paul Grof ... |
| title_full_unstemmed | Clinical evaluation of psychotropic drugs for psychiatric disorders principles and proposed guidelines Paul Grof ... |
| title_short | Clinical evaluation of psychotropic drugs for psychiatric disorders |
| title_sort | clinical evaluation of psychotropic drugs for psychiatric disorders principles and proposed guidelines |
| title_sub | principles and proposed guidelines |
| topic | Maladies mentales - Chimiothérapie Psychotropes Drug Evaluation standards Drug Utilization Mental Disorders drug therapy Mental illness Chemotherapy Psychotropic Drugs Psychotropic Drugs adverse effects Psychotropic drugs Substance-Related Disorders Evaluation (DE-588)4071034-8 gnd Klinische Prüfung (DE-588)4031192-2 gnd Psychopharmakon (DE-588)4047729-0 gnd |
| topic_facet | Maladies mentales - Chimiothérapie Psychotropes Drug Evaluation standards Drug Utilization Mental Disorders drug therapy Mental illness Chemotherapy Psychotropic Drugs Psychotropic Drugs adverse effects Psychotropic drugs Substance-Related Disorders Evaluation Klinische Prüfung Psychopharmakon |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=005025244&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV005800405 |
| work_keys_str_mv | AT grofpaul clinicalevaluationofpsychotropicdrugsforpsychiatricdisordersprinciplesandproposedguidelines |